December 2011 | Oncology & Biotech News

Exelixis Finds Great Promise in Cabozantinib

December 28, 2011

The investigational compound cabozantinib (formerly known as XL184) has generated much excitement in recent years for its ability to target multiple pathways involved in the development of cancer.

Room for Improvement: Reporting Near-Misses and Errors in Radiation Oncology

December 27, 2011

A new study presented at the 2011 annual meeting of the American Society for Radiation Oncology (ASTRO) found that 97% of radiation oncology team members believe they have a responsibility to report near-misses and errors...

Biomarker Identifies Patients With Advanced Lung Cancer Who Will Gain Most From Add-On Cetuximab

December 22, 2011

Investigators reported that high tumor EGFR expression is a predictive biomarker that defines patients with advanced NSCLC who are most likely to derive a survival benefit from the addition of cetuximab to platinum-based, first-line chemotherapy.